A Phase 2a Open-Label, Multicenter, First-in-Human Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDB-1829 in Combination with Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer(mCRPC)

Start Date15 Apr 2027

Sponsor / Collaborator

Interdict Bio, Inc.

NCT07782112

/ Not yet recruitingPhase 3IIT

PEACE-9 - ESCALATE-RT: A Phase III Randomized Study in Patients With High-risk PSA Relapse After Local Therapy Treated With Enzalutamide Plus Androgen Deprivation Therapy and Comparing MDT ± Pelvic Radiotherapy Versus no Further Treatment

The goal of this clinical trial is to learn if adding metastasis-directed radiotherapy with or without pelvic salvage radiotherapy, to intermittent prostate cancer drugs (intensified hormone therapy) can delay the need to restart these drugs in men with oligometastactic prostate cancer recurrence.
In practice, this study is open to men whose PSA level (a blood marker of cancer activity) is rising as defined by biochemical recurrence, and who have 1 to 5 areas of cancer spread (1 to 5 metastases defining oligometastatic status) found on a specialized scan (PSMA PET/CT).
Since intensified hormone therapy, including androgen deprivation therapy combined with a next-generation hormone therapy, represents the standard treatment strategy for these patients, researchers want to find out if adding radiation therapy can help patients to spend more time off cancer drugs while keeping their cancer under control.
The main questions this trial aims to answer are:
* Does adding radiation therapy to each metastases with or without pelvic area, lengthen the time before participants need to restart drug treatment?
* Does adding radiation therapy increase the number of participants whose PSA drops to a very low level (0.2 ng/mL or lower)?
* Does adding radiation therapy affect participants' quality of life?
Researchers will randomly assign participants (chosen by chance) to receive either enzalutamide (next-generation hormone therapy) plus androgen-deprivation therapy (first-generation hormone therapy ) alone, or the same association of these drugs combined with radiation therapy aimed at each metastases with or without pelvic area.
This comparison will show whether adding radiation therapy helps participants reach a deeper PSA response and go longer without needing cancer drugs.
Participants will:
* Take enzalutamide and androgen-deprivation therapy for 9 months
* Have an equal chance of also receiving radiation therapy to each metastases with or without pelvic area
* Stop drug treatment after 9 months if their PSA drops below 0.2 ng/mL, a level showing the cancer is well controlled
* Restart drug treatment if their PSA rises again during the treatment-free period
* Have regular blood tests and clinic visits to check their PSA, testosterone, and overall health
* Complete short quality-of-life questionnaires during the study
* Take part in a study conducted at several hospitals in Switzerland, Belgium, and France.

Start Date01 Nov 2026

Sponsor / Collaborator

Ente Ospedaliero Cantonale

NCT07795177

/ Not yet recruitingPhase 2IIT

A Prospective Study Based on Spatial Multi-Omics for Predicting the Efficacy of Androgen Deprivation Therapy Combined With Second-Generation Novel Endocrine Therapeutic Agents in Metastatic Hormone-Sensitive Prostate Cancer.

This study plans to enroll patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) and conduct a prospective, single-center, observational study. By performing whole-exome sequencing (WES), Xenium spatial transcriptomics, and PhenoCycler-Fusion spatial single-cell proteomics (PCF analysis) on tumor tissue samples, we aim to comprehensively delineate the molecular landscape of patients with different spatial multi-omic profiles in the real-world setting. We will investigate the associations between these molecular features and differential treatment responses to various therapeutic regimens, and further construct predictive models of treatment response. Ultimately, this will enable precise evaluation of treatment outcomes across distinct molecular subtypes and provide evidence to support individualized precision diagnostics and therapeutics for patients with mHSPC.

Start Date01 Oct 2026

Sponsor / Collaborator

Anhui Medical University

100 Clinical Results associated with Enzalutamide

100 Translational Medicine associated with Enzalutamide

100 Patents (Medical) associated with Enzalutamide

4,160

Literatures (Medical) associated with Enzalutamide

01 Jan 2027·CELLULAR SIGNALLING

Targeting the HIF-1α–BSG metabolic circuit reverses enzalutamide resistance in prostate cancer

Article

Author: Yu, Yongjiang ; Xu, Yulin ; Liao, Haihong ; Huang, Jiacheng ; Guo, Xiuchen ; Chen, Zhiwei

BACKGROUND:

Enzalutamide resistance limits durable control of castration-resistant prostate cancer (CRPC), but the mechanisms coordinating metabolic adaptation, cellular plasticity, and residual androgen receptor (AR) signaling remain incompletely understood. We investigated whether BSG, encoding basigin/CD147, contributes to this resistant state.

METHODS:

We integrated reanalysis of an androgen-responsive reporter-based CRISPR activation screen with bulk and single-cell transcriptomic datasets, clinical specimens, and outcome data. Reciprocal BSG loss- and gain-of-function experiments were performed in parental and enzalutamide-resistant LNCaP and C4-2 cells. Drug response, cellular plasticity, glycolytic activity, hypoxia/HIF1A perturbation, pathway-directed inhibition, and resistant xenografts were evaluated.

RESULTS:

BSG-activating guides were enriched in unsorted and androgen-responsive, but not androgen-independent, enzalutamide-resistant populations. BSG was elevated in resistant models and high-Gleason-score tumors, and high expression was associated with shorter progression-free survival. Single-cell analysis identified a CRPC-enriched tumor-cell state with high BSG and SLC16A3 expression, increased glycolysis and hypoxia-related activity, enhanced developmental plasticity, and retained AR-target gene expression. BSG depletion increased enzalutamide responsiveness and suppressed proliferation, clonogenic survival, migration, invasion, sphere formation, and stemness and epithelial-mesenchymal transition programs in resistant cells, whereas BSG overexpression produced reciprocal effects in parental cells. BSG depletion reduced AR and PSA abundance in LNCaP EnzR cells. It also reduced extracellular acidification, lactate production, glucose uptake, and the abundance of HK2, LDHA, MCT1, and MCT4. Hypoxia or HIF1A overexpression increased BSG-associated metabolic and plasticity programs, whereas BSG depletion attenuated most HIF-1α-induced changes without materially reducing HIF-1α. In resistant xenografts, BSG depletion or PX-478 enhanced tumor suppression by enzalutamide.

CONCLUSIONS:

BSG contributes to an AR-retaining, hypoxia-associated glycolytic and plastic state that supports enzalutamide resistance.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis

Article

Author: Appukkuttan, Sreevalsa ; Rettig, Matthew ; Steel, Paul ; Padula, William V. ; Cohen, Benjamin G. ; Kalayeh, Bashir

AIMS:

To evaluate the cost-effectiveness of darolutamide plus androgen deprivation therapy (DARO+ADT) versus enzalutamide plus ADT (ENZA+ADT) and apalutamide plus ADT (APA+ADT) as first-line androgen receptor pathway inhibitor (ARPI) double therapies for metastatic castration-sensitive prostate cancer (mCSPC) from a US healthcare sector perspective.

METHODS:

A partitioned survival model with three health states (progression-free mCSPC, progressed mCRPC, and death) projected lifetime costs and outcomes over a 30-year horizon with monthly cycles. DARO+ADT efficacy was derived from the ARANOTE trial; comparative efficacy for ENZA+ADT and APA+ADT was estimated via network meta-analysis-derived hazard ratios. Costs (drug acquisition, adverse event management, subsequent therapy, end-of-life care) and utilities were derived from trial data, published literature, and US cost sources. Costs and outcomes were discounted at 3% annually. Deterministic, probabilistic, and two-way sensitivity analyses assessed parameter uncertainty at a willingness-to-pay threshold of $150,000/QALY.

RESULTS:

DARO+ADT generated 4.18 QALYs versus 4.03 (ENZA+ADT) and 3.99 (APA+ADT), driven by longer treatment persistence and lower adverse-event-related disutility. Versus ENZA+ADT, DARO+ADT yielded 0.15 incremental QALYs at $12,564 incremental cost (ICER: $85,108/QALY; net monetary benefit: $9,579). Versus APA+ADT, DARO+ADT was dominant (0.19 additional QALYs, $4,293 lower cost; net monetary benefit: $33,153). Two-way sensitivity analyses varying off-treatment utilities and post-discontinuation therapy costs showed that DARO+ADT remained cost-effective versus ENZA+ADT and dominant versus APA+ADT, respectively, across the parameter ranges tested. Probabilistic sensitivity analysis showed DARO+ADT was cost-effective in 51% and 52% of simulations versus ENZA+ADT and APA+ADT, respectively, which demonstrates uncertainty around the incremental findings.

LIMITATIONS:

The analysis relies on indirect comparisons and extrapolated modeling, factors that may limit the generalizability of the findings.

CONCLUSIONS:

DARO+ADT was cost-effective versus ENZA+ADT and dominant versus APA+ADT, driven by improved tolerability and treatment persistence, supporting its value as a first-line mCSPC option.

01 Dec 2026·PHARMACOLOGY & THERAPEUTICS

Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention

Review

Author: Pillozzi, Serena ; Rossi, Virginia ; Calandrelli, Chiara ; Pratesi, Luca ; Roviello, Giandomenico ; Mela, Marinella Micol ; Mancini, Silvia ; Lapucci, Andrea ; Roberts, Robin ; Cerbone, Linda ; Koatale, Palesa Caroline ; Santoni, Matteo ; Izzi, Martina ; Antonuzzo, Lorenzo ; Matthews, Diana ; Catalano, Martina ; Vascotto, Ismaela Anna ; Perrella, Armando

Biochemical recurrence after definitive local therapy for prostate cancer represents a heterogeneous clinical state, with patients exhibiting short prostate-specific antigen (PSA) doubling time at particularly high risk of metastatic progression and cancer-related mortality. Persistent androgen receptor signaling plays a central role in sustaining occult micrometastatic disease, providing a strong biological rationale for early therapeutic intervention. The phase III EMBARK trial demonstrated that intensification of androgen receptor pathway inhibition with enzalutamide, administered either in combination with androgen deprivation therapy or as monotherapy, significantly improves metastasis-free survival and delays disease progression in patients with high-risk biochemical recurrence, with an overall survival benefit observed for combination therapy. Importantly, EMBARK introduced a PSA-guided treatment-suspension strategy designed to reduce cumulative treatment exposure. These findings redefine high-risk biochemical recurrence as an actionable disease state and support the integration of enzalutamide-based approaches into contemporary prostate cancer treatment algorithms.

823

News (Medical) associated with Enzalutamide

21 Oct 2026

·www.fiercebiotech.com

Astellas links up with AI Proteins in $400M computational drug discovery deal

Japan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially worth $400 million. AI Proteins crafts miniproteins with the aid of its computational design platform that the company said have demonstrated binding activity “beyond what's possible with traditional nature-derived biologics,” according to an Oct. 21 release . The concept behind the platform is to essentially flip the drug discovery script by creating built-for-purpose molecules from scratch rather than seeking biological solutions. “Every biologic medicine on the market today is based on a molecule borrowed from nature that evolved to do something else,” AI Proteins CEO and founder Chris Bahl, Ph.D., said in the release. “Designing miniproteins de novo lets us work from the other direction, meaning we specify what a medicine needs to do, then build a molecule from scratch to do precisely that.” AI Proteins will receive an undisclosed upfront fee from Astellas, with milestones bringing the deal's potential value to north of $400 million. Astellas will take responsibility for development, regulatory processing and commercialization of any assets resulting from the partnership. Astellas' push into AI territory began last decade. The company started bringing the technology into its development processes in 2019, using its “human-in-the-loop” platform to operationalize data collection and research. Now folding AI Proteins' platform into the mix, Astellas hopes to expand its early-stage pipeline. With the upcoming patent cliff for the blockbuster cancer drug Xtandi, which brought in $6 billion in sales last year, Astellas CEO Naoki Okamura told Fierce in January that the company would rather “invest in [the] much longer term” rather than plastering the cracks through traditional pharma business development. The deal with AI Proteins demonstrates that investment thesis, fitting Astellas' agnostic approach to therapeutic areas and modalities. “Our collaboration with AI Proteins reflects our strategic focus on strengthening our early-stage research pipeline through partnerships that provide access to novel biology, differentiated technologies and new therapeutic possibilities,” Morten Sogaard, senior vice president of Astellas Innovation Lab, said in the release. “By combining AI Proteins' advanced de novo protein design capabilities with Astellas' expertise in translating scientific breakthroughs into innovative medicines, we aim to accelerate the discovery of high-quality therapeutic candidates that can help fuel long-term innovation and support our pipeline-led growth strategy,” Sogaard added. Over the last couple of years, AI Proteins has racked up a few discovery-focused partnerships with a similar aim, including a $400 million deal with Bristol Myers Squibb at the end of 2024 and an R&D collaboration with oral biologic platform company Vivtex earlier that year. It has also explored radioligand therapies alongside the University of Missouri through a collaborative research agreement. AI Proteins' most recent funding round was a series A worth $41.5 million in November 2025, following an initial seed round of $18.2 million back in 2022. Where Big Pharma is placing its bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below:

21 Oct 2026

·www.biospace.com

IDWeek 2026: New Exploratory Analyses Evaluate XOCOVA® (ensitrelvir) Following COVID-19 Exposure, Including Breakthrough Infections and Infection Present at Baseline

A pooled analysis from the global SCORPIO clinical program showed potent antiviral activity with ensitrelvir across age, vaccination status and risk for severe disease New data underscores that even mild-to-moderate COVID-19 may worsen and exacerbate underlying chronic conditions, supporting the importance of prevention OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) will present new exploratory analyses from the global Phase 3 SCORPIO-PEP study, virology data from across the ensitrelvir phase 3 program, and new insights on the continued burden of COVID-19 at IDWeek 2026. XOCOVA ® (ensitrelvir) was approved in May 2026 by the U.S. Food and Drug Administration (FDA) for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19. 1 The approval was based on positive results from SCORPIO-PEP, a global, double-blind, randomized, placebo-controlled Phase 3 study. In the primary analysis population, XOCOVA significantly reduced the risk of developing symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compared with placebo (ensitrelvir n=1,030; placebo n=1,011). 1,2 In SCORPIO-PEP, XOCOVA was generally well tolerated, with similar rates of adverse events across groups (15.1% in the ensitrelvir group (n=1,190) and 15.5% in the placebo group (n=1,187)). 2 The most common adverse events (regardless of causality) occurring in greater than or equal to 1% of the XOCOVA group and at a greater frequency compared to placebo were headache, diarrhea, and cough. 1,2 There were no reports of altered taste (dysgeusia) attributed to XOCOVA in the trial. 2,3 Exploratory SCORPIO-PEP Analyses Describe Symptom Severity and Viral Outcomes Among Participants with Breakthrough Infection or Infection Present at Baseline In an oral presentation at IDWeek 2026, Shionogi will report new exploratory analyses from the SCORPIO-PEP study evaluating participants who had breakthrough infections or were already infected at baseline. 4 Among breakthrough infection cases (based on RT-PCR positivity regardless of symptoms) in the primary analysis population, the mean maximum viral RNA levels were lower in participants receiving ensitrelvir compared to those receiving placebo (3.1 vs 4.3 mean log10 copies/mL, respectively, seen in 144 and 217 breakthrough infection cases, respectively). 4 In household contacts who were infected with SARS-CoV-2 at the time of enrollment (confirmed positive by baseline central RT-PCR despite testing negative on a local screening test and being asymptomatic; n=237), numerically lower mean viral RNA levels were also observed with ensitrelvir in comparison to placebo on Days 3 and 6. 4 In the primary analysis population, a numerically lower proportion of participants with symptomatic breakthrough infections taking ensitrelvir developed severe symptoms, compared with those taking placebo (severe symptoms were reported in 8/28 or 28.6% of individuals receiving ensitrelvir compared with 48/89 or 53.9% of individuals receiving placebo). 4 Similarly, numerically lower mean total symptom scores earlier in the study and lower mean maximum total symptom scores were observed in participants receiving ensitrelvir compared with placebo (mean maximum total scores were 6.6 vs 8.9 respectively). 4 In participants receiving ensitrelvir who were infected with SARS-CoV-2 at the time of enrollment despite testing negative on a local screening test and being asymptomatic, a numerically lower proportion developed severe symptoms compared with placebo (severe symptoms were reported in 2/18 or 11.1% of individuals receiving ensitrelvir compared with 9/24 or 37.5% of individuals receiving placebo). 4 Similarly, numerically lower mean total symptom scores earlier in the study and mean maximum total symptom scores were observed in those receiving ensitrelvir compared with placebo. 4 “SCORPIO-PEP showed that early administration of ensitrelvir following household exposure reduced the risk of symptomatic COVID-19,” said Simon Portsmouth, MD, FRCP, Senior Vice President, Head of Clinical Development, Shionogi Inc. “This exploratory analysis provides additional insight into the antiviral activity of ensitrelvir on viral load and symptom outcomes among participants who developed COVID-19. These observations add to our understanding of the potential outcomes associated with early administration of ensitrelvir following household exposure.” Pooled Phase 3 Study Data Analysis Shows Potent Antiviral Activity of Ensitrelvir Through Observed Reductions in Infectious Virus In a separate poster presentation, investigators will report findings from a post-hoc pooled analysis of two Phase 3 studies designed to assess infectious-virus-based virologic outcomes across a broad range of participants with confirmed COVID-19 infection. 6 Unlike viral RNA detection by RT-PCR, which may identify noninfectious viral remnants, infectious-virus measurements assess the presence of replication-competent virus and can provide additional insight into antiviral activity. 5,6 By Day 4, participants who received ensitrelvir (375 mg on Day 1, then 125 mg on Days 2–5; n=484) had numerically greater reductions in infectious virus titers than those who received placebo (n=487) (difference in least-squares mean of 0.21 log10 TCID 50 /mL). 6 Similar results were observed across subgroups regardless of age, vaccination status, and risk factors for severe COVID-19. Also on day 4, a higher proportion of ensitrelvir recipients had undetectable infectious viral load compared to those receiving placebo (95.7% [463/484] vs 72.1% [351/487]). 6 “With data pooled from two Phase 3 studies, this analysis represents the most extensive infectious virus dataset reported for a COVID-19 antiviral to date, and it helps to further characterize ensitrelvir’s effect on active viral replication,” said Florin Draica, MD, CMD, MBA, Senior Vice President, U.S. Medical Affairs, Shionogi Inc. “Although these results are exploratory, the observed reductions in infectious virus provide additional support of ensitrelvir’s antiviral activity and warrant further evaluation of their potential implications for infectivity and transmission.” Systematic Literature Review Highlights the Continued Burden of COVID-19 and Its Impact on Underlying Chronic Conditions Shionogi will also present a systematic literature review evaluating the impact of acute COVID-19 on individuals with underlying chronic conditions during the Omicron era or in earlier time periods. The review included 35 observational studies assessing clinical outcomes, health-related quality of life (HRQoL), and healthcare resource utilization (HCRU). 7 Across the studies reviewed, acute COVID-19 was associated with worsening, exacerbation, or relapse of underlying chronic conditions spanning respiratory, neurologic, cardiovascular, renal, and other disease areas. 7 More than half of studies evaluating clinical outcomes (17 out of 33) reported statistically significant worsening of underlying chronic conditions such as asthma, COPD, multiple sclerosis and CKD, following acute COVID-19. 7 COVID-19 was also associated with worsening outcomes in five of eight studies reporting on HRQoL and increased hospitalization frequency or extended hospital length of stay in four of the six studies reporting on HCRU. 7 “Across studies in this review, acute COVID-19 during the Omicron predominance was associated with worsening or exacerbation of underlying chronic conditions. Specifically, we found that COVID-19 infection, even mild or moderate, was associated with reduced health-related quality of life and increased healthcare resource utilization,” said Alpesh N. Amin, M.D., Professor, Founding Chief and Executive Director of Hospital Medicine & Palliative Medicine, and Co-Director & Medical Director of the Institute for Precision Health at the University of California, Irvine. “These findings reinforce the continued burden of COVID-19 and underscore the importance of prevention, especially among people living with chronic conditions.” The Ongoing Impact of COVID-19 COVID-19 remains highly transmissible, driven by Omicron and its subvariants, and up to 47% of people living with an infected individual may develop COVID-19. 8,9 The U.S. Centers for Disease Control and Prevention estimates that between October 1, 2025, and September 26, 2026, there were 5.2-14.6 million new cases in the U.S., resulting in 1.1-2.7 million outpatient visits, 170,000-270,000 hospitalizations and 17,000-48,000 deaths. 10 Beyond acute infection, COVID-19, even mild-to-moderate, may worsen underlying chronic conditions and can have lasting health impacts. Studies have reported increased rates of new and worsening neurologic, cardiovascular, respiratory, and chronic kidney conditions in the year following COVID-19 infection. 11-19 COVID-19 also disproportionately affects older adults with greater risk for severe illness and death in close-community settings, such as long-term care facilities. 20 About SCORPIO-PEP The global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, assessed the safety and efficacy of XOCOVA as post-exposure prophylaxis for COVID-19. The study was conducted from June 2023-September 2024. It included 2,387 study participants aged 12 years and older with a negative local screening test for SARS-CoV-2 infection and no symptoms at the time of enrollment, who were exposed to a person living in their household with symptomatic COVID-19. More than 98% of household contacts tested positive for antibodies against SARS-CoV-2 N (nucleocapsid) or S (spike) proteins, indicating that nearly all had evidence of previous SARS-CoV-2 infection or vaccination, or both. Study participants were randomly assigned at a 1:1 ratio to receive XOCOVA (375 mg on Day 1 and 125 mg on Days 2-5) or placebo, once daily for five days, and began treatment within 72 hours of when the household member with COVID-19 began showing symptoms. Results from SCORPIO-PEP were published in the New England Journal of Medicine . SCORPIO-PEP is the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing COVID-19 following exposure to an infected individual.* About XOCOVA XOCOVA ® (ensitrelvir) is a SARS-CoV-2 main protease inhibitor created through joint research between Hokkaido University and Shionogi. SARS-CoV-2 has an enzyme called the main protease, which is essential for the replication of the virus. XOCOVA suppresses the replication of SARS-CoV-2 by selectively inhibiting the main protease. XOCOVA is approved in the U.S., Japan and European Union for post-exposure prophylaxis of COVID‑19 in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19. XOCOVA received emergency regulatory approval in Japan in November 2022 and full approval in March 2024 for the treatment of COVID-19 in adults and adolescents 12 years of age and older. XOCOVA received supplemental approval in Japan in June 2026 for pediatric patients aged 6 to under 12 years who weigh at least 20 kg for the treatment of COVID-19. XOCOVA is not approved for the treatment of COVID-19 in the U.S. U.S. INDICATION XOCOVA (ensitrelvir) is a prescription medicine used to help prevent coronavirus disease 2019 (COVID-19) in adults and children aged 12 years and older following contact with a person who has COVID-19 (post-exposure prophylaxis). It is not known if XOCOVA is safe and effective in children under age 12. IMPORTANT SAFETY INFORMATION Do not take XOCOVA if you are: allergic to ensitrelvir or any of the ingredients in XOCOVA. take any of the following medicines, as these may interact with XOCOVA and may cause severe or life-threatening side effects or death: apalutamide, carbamazepine, colchicine, dihydroergotamine, enzalutamide, eplerenone, ergotamine, finerenone, ivabradine, lomitapide, lumacaftor/ivacaftor, lurasidone, methylergonovine, phenytoin, pimozide, quinidine, rifampin, St. John’s wort, simvastatin, triazolam or voclosporin. These are not the only medicines that may cause serious or life-threatening side effects if taken with XOCOVA. XOCOVA may increase or decrease the levels of many medicines in your body. Tell your healthcare provider (HCP) about all the medicines you take because additional laboratory tests or dose changes of your other medicines may be necessary during XOCOVA use. Your HCP may tell you about specific symptoms to watch for that may indicate you need to stop or decrease the dose of some of your other medicines. Before taking XOCOVA, tell your HCP about all your medical conditions, including if you: are pregnant or plan to become pregnant. XOCOVA may harm your unborn baby. For females who are able to become pregnant, your HCP will check with you to see if you are pregnant before starting XOCOVA. Use effective birth control (contraception) during XOCOVA use and for 2 weeks after the final dose. Tell your HCP right away if you become pregnant or think you may be pregnant during XOCOVA use. are breastfeeding or plan to breastfeed. It is not known if XOCOVA passes into your breast milk. Do not breastfeed during XOCOVA use and for 2 weeks after the final dose. Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your HCP can tell you if it is safe to take XOCOVA with other medicines. Do not start a new medicine without telling your HCP. What are the possible side effects of XOCOVA? XOCOVA may cause serious side effects, including: Allergic reactions, including severe allergic reactions (anaphylaxis). Stop taking XOCOVA and get medical help right away if you get any of the following allergic reaction symptoms: skin rash; hives; itching; swelling of the mouth, lips, tongue, or face; trouble swallowing or breathing; throat tightness; dizziness or feeling lightheaded; stomach-area (abdomen) pain; or vomiting. The most common side effects of XOCOVA include : headache, diarrhea, and cough. These are not all possible side effects of XOCOVA. For more info, ask your HCP or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088 . Please see full Prescribing Information , including Patient Information , for XOCOVA. About Shionogi Inc. Shionogi Inc. is a U.S. subsidiary of Shionogi & Co., Ltd., a global research‑driven pharmaceutical company. Since 1878, Shionogi has been developing new treatments to improve patients’ lives worldwide. Today in North America, we are focused on infectious and rare diseases, and our portfolio includes an antibiotic for serious infections caused by susceptible Gram-negative bacteria, an oral antiviral for post-exposure prophylaxis of COVID-19 and a therapy for amyotrophic lateral sclerosis (ALS). Together with our subsidiaries Qpex Biopharma Inc. and Shionogi Canada Inc., we are continuing to innovate across infectious disease, rare disease and additional high‑need therapeutic areas. Learn more at shionogi.com . About Shionogi & Co., Ltd. Shionogi & Co., Ltd. is a 148-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain and CNS disorders. Shionogi’s research and development currently targets two therapeutic areas: infectious diseases and diseases with unmet medical needs, including rare diseases, allergy/inflammation, oncology, hearing loss, and sleep apnea. For more information on Shionogi & Co., Ltd., please visit . Forward-Looking Statements This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. * Literature search conducted in May 2026 References 1 XOCOVA (ensitrelvir) Prescribing Information. Available from: . Accessed July 6, 2026. 2 Hayden FG, Shinkai M, et al. Ensitrelvir for COVID-19 postexposure prophylaxis in household contacts. N Engl J Med . 2026;394(19):1905-1915. doi: 10.1056/NEJMoa2509306 . 3 Hayden FG, Shinkai M, Clark TW, et al. Ensitrelvir for COVID-19 postexposure prophylaxis in household contacts. Supplementary Appendix. N Engl J Med . 2026;394(19). Available from: . 4 Fukushi A, Nobori H, Sakaguchi H, et al. Early Pre-Symptomatic Treatment with Ensitrelvir Among PCR-Positive, SARS-CoV-2-Exposed and Infected Household Contacts: SCORPIO-PEP Subpopulation Analysis. Presented at: IDWeek 2026; Washington, D.C., United States. 5 Binnicker MJ. Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods To Be Surrogates for Replication-Competent Virus. Journal of Clinical Microbiology . 2021;59(11):e00469-21. doi:10.1128/JCM.00469-21. 6 Hurt AC, Nobori H, Sakaguchi H, et al. Reduction of Infectious SARS-CoV-2 and Viral RNA with Ensitrelvir: A Pooled Analysis of SCORPIO-SR and SCORPIO-HR Trials [poster presentation]. Presented at: IDWeek 2026; Washington, D.C., United States. 7 Draica F, Verdi D, Fedele M, et al. Impact of Acute COVID-19 on Underlying Chronic Conditions: Systematic Literature Review [poster presentation]. Presented at: IDWeek 2026; Washington, D.C., United States. 8 Baker JM, Nakayama JY, O’Hegarty M, et al. Household transmission of SARS-CoV-2 in five US jurisdictions: comparison of Delta and Omicron variants. PLoS One. 2025;20(1):e0313680. doi:10.1371/journal.pone.0313680. 9 Madewell ZJ, Yang Y, Longini IM Jr, et al. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. JAMA Netw Open. 2022;5(4):e229317. doi:10.1001/jamanetworkopen.2022.9317. 10 Centers for Disease Control and Prevention [Internet]. Preliminary 2025-2026 COVID-19 burden estimates. Available from: 11 Xie Y, Xu E, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590. doi:10.1038/s41591-022-01689-3. 12 Sax PE, Draica F, et al. New onset conditions, exacerbations and worsening of underlying conditions following COVID-19 infection [poster presentation]. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); 2026; Denver, CO, United States. 13 Graham EL, Clark JR, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 “long haulers.” Ann Clin Transl Neurol. 2021;8(5):1073-1085. doi:10.1002/acn3.51350. 14 Xie Y, Xu E, Bowe B, et al. Risks of mental health outcomes in people with COVID-19: a cohort study. BMJ. 2022;376:e068993. doi:10.1136/bmj-2021-068993. 15 Srivastava S, Garg I. Post-COVID-19 infection: long-term effects on liver and kidneys. World J MetaAnal. 2021;9(3):220-233. doi:10.13105/wjma.v9.i3.220. 16 Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993-998. doi:10.15585/mmwr.mm6930e1. 17 Kwok WC, Chau CH, Tam TCC, et al. Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity. Sci Rep. 2024;14(1):13881. doi:10.1038/s41598-024-64670-9. 18 Conway SE, Healy BC, Zurawski J, et al. COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders. Mult Scler Relat Disord. 2022;63:103946. doi:10.1016/j.msard.2022.103946. 19 Chen IW, Chang LC, Ho CH, et al. Association between COVID-19 and the development of chronic kidney disease in patients without initial acute kidney injury. Sci Rep. 2025;15(1):10924. doi:10.1038/s41598-025-96032-4. 20 Gravenstein S, Cooke CE, Verdi D, et al. Current impact of COVID-19 in long-term care facilities in the United States: a systematic literature review. Sr Care Pharm. 2026;41(5):167-186. doi:10.4140/TCP.n.2026.167. Contacts For Further Information: SHIONOGI Website Inquiry Form: U.S. Media: ShionogiCommunications@shionogi.com Shionogi Europe Press Office: pressoffice@shionogi.eu

Clinical ResultPhase 3Drug Approval

21 Oct 2026

·www.biospace.com

Foundation Medicine and Joint Collaborators to Present 12 Abstracts at the ESMO Congress 2026

Foundation Medicine to host series of expert-led booth talks to highlight how its driving innovation in precision diagnostics BOSTON--(BUSINESS WIRE)-- Foundation Medicine, Inc ., a global, patient-focused precision medicine company, today announced the acceptance of 12 abstracts for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27, 2026, in Madrid, Spain. These presentations cover key topics such as MTAP loss, the clinical impact of clonal hematopoiesis (CH), and the expanded utility of circulating tumor DNA (ctDNA) tumor fraction. In addition to 10 poster presentations, Foundation Medicine’s research will be featured in two Rapid Oral Sessions: 2218RO - Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC) Friday, October 23 at 13:00 CEST in Bilbao Auditorium – Hall 3 2219RO - Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC) Friday, October 23 at 13:00 CEST in Bilbao Auditorium – Hall 3 Foundation Medicine will also host a series of expert-led booth talks in its booth 1030 in Hall 10: Saturday, October 24 13:00 – 13:15 CEST - Don’t Miss the Loss: Unlocking MTAP , PTEN & Others Through Robust Copy Number Detection 13:25 – 13:40 CEST - Breaking the Sensitivity Floor: The Science of Ultra-Sensitive MRD 13:50 – 14:05 CEST - Detect MTAP Loss More Often in Your Clinical Trials: Don’t Miss the Signal 14:15 – 14:30 CEST – Don’t Miss Fusions and Complex Variants with FoundationOne ® RNA Sunday, October 25 13:00 – 13:15 CET – Translating Ultra-Sensitive MRD to Clinical Practice: Detection and Monitoring of ctDNA Using Structural Variants 13:30 – 13:45 CET – Don’t Miss the Loss: Unlocking MTAP , PTEN & Others Through Robust Copy Number Detection 14:00 – 14:15 CET – Redefining the Standard in MRD: Structural Variants & Digital PCR for Ultra Sensitivity & High Specificity Monday, October 26 13:00 – 13:15 CET- The Role of Longitudinal ctDNA Testing in Early and Advanced Stage Cancer 13:30 – 13:45 CET – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection 14:00 – 14:15 CET – HRD Signature Without Limits: Go Beyond Ovarian To learn more, visit Foundation Medicine in person at booth 1030 in Hall 10 or book a meeting at . Full List of Foundation Medicine’s Abstracts at ESMO Congress 2026 Presentation Number Title Product Friday, October 23 2218RO Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC) FoundationOne ® Liquid CDx 2219RO Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC) FoundationOne Liquid CDx, FoundationOne ® Monitor 4294P The Tumor-Agnostic (TA) Therapy Biomarker Landscape: Established and Emerging Markers Across 385,420 Solid Tumors FoundationOne ® CDx 4304P Comprehensive Genomic Profiling in Lacrimal Duct Carcinoma Reveals HER2-Driven Biology and Emerging Therapeutic Targets FoundationOne CDx 4762P Homologous Recombination Signature (HRDsig) in Adenocarcinoma (ACB) and Urachal Carcinoma (UrCA) of the Bladder: Implications for PARP Inhibitor (PARPi) Treatment FoundationOne CDx 4308P Genomic Landscape of KRAS G12D Mutant Non-Small Cell Lung Cancer (NSCLC) and Comparison with KRAS non-G12D Mutant and KRAS Wild Type Cases FoundationOne CDx 4372P MTAP Loss and HPV Status in Head and Neck Squamous Cell Carcinoma (HNSCC): A Genomic Landscape Study FoundationOne CDx 2232P Longitudinal ctDNA tumor fraction (TF) as a prognostic biomarker in bone-dominant metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 ± olaparib: Results from the phase 2 COMRADE trial FoundationOne Liquid CDx, FoundationOne Monitor 4750P Overall survival (OS) and mature safety results of SURE-02, a phase 2 study of neoadjuvant Sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant Pembro, in patients with muscle-invasive bladder cancer (MIBC) N/A 4283P ctDNA tumor fraction captures tumor biology and predicts resistance to systemic therapy across solid tumors and NSCLC FoundationOne Liquid CDx Monday, October 26 3765P Homologous Recombination Signature (HRDsig) in Angiosarcoma (AngSarc) FoundationOne CDx 2628P Genomic and Biomarker Landscape of MTAP loss/KRAS G12D mutant vs. MTAP loss/KRAS non-mutated Advanced NSCLC FoundationOne CDx About Foundation Medicine Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at and follow us on LinkedIn , X , YouTube , Facebook , Instagram and BlueSky . About FoundationOne ® CDx FoundationOne ® CDx is for prescription use only and is an FDA-approved qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy which may pose a risk. For the complete label, including companion diagnostic indications and important risk information, please visit . About FoundationOne ® Liquid CDx FoundationOne ® Liquid CDx is for prescription use only and is an FDA-approved qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes, rearrangements in 8 genes and copy number alterations in 3 genes, and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. When considering eligibility for ROZLYTREK ® based on the detection of NTRK1/2/3 and ROS1 fusions, or for TEPMETKO ® based on the detection of MET SNVs and indels that lead to MET exon 14 skipping, testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit . About FoundationOne ® RNA FoundationOne ® RNA is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne RNA has not been cleared or approved by the U.S. Food and Drug Administration. FoundationOne RNA is a test for solid tumors which utilizes RNA sequencing to interrogate 318 cancer-related genes to capture gene fusions and rearrangements. A negative result does not rule out the presence of an alteration. Genomic findings are not prescriptive or conclusive for labeled use of any specific therapeutic product. About FoundationOne ® Monitor FoundationOne ® Monitor is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. This test has not been cleared or approved by the U.S. Food and Drug Administration. FoundationOne Monitor is a test for patients with solid malignant neoplasms that detects and longitudinally tracks circulating tumor DNA (ctDNA), reported as ctDNA tumor fraction (a determination of the amount of ctDNA as a fraction of total cell free DNA in a blood sample) as a biomarker for tumor content in the blood. Treatment decisions are the responsibility of the treating physician. ctDNA tumor fraction determination sensitivity may be limited if blood collection occurs within two weeks of surgery. ctDNA not detected status does not definitively indicate the absence of cancer and declining ctDNA tumor fraction does not necessarily indicate a response to therapy. This test is not designed to detect or report germline variation, nor does it infer hereditary cancer risk for a patient. This test is expected to have limited sensitivity in some cancer types due to limited ctDNA shed. Foundation Medicine and FoundationOne ® are registered trademarks of Foundation Medicine, Inc. Contacts Media Contact: Danielle Johns, 845-304-7408 newsroom@foundationmedicine.com

Clinical ResultPhase 2Phase 3

100 Deals associated with Enzalutamide

External Link

KEGG	Wiki	ATC	Drug Bank
D10218	Enzalutamide	L02BB04	DB08899

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	South Korea	Astellas Pharma Korea, Inc.	03 Dec 2024
Castration-sensitive prostate cancer	United States	Astellas Pharma US, Inc.	16 Nov 2023
HRR Gene-mutated Castration-Resistant Prostate Cancer	United States	Pfizer Inc.	20 Jun 2023
Metastatic Prostate Carcinoma	Japan	Astellas Pharma, Inc.	29 May 2020
Castration-Resistant Prostatic Cancer	European Union	Astellas Pharma Europe Ltd.	21 Jun 2013
Castration-Resistant Prostatic Cancer	Iceland	Astellas Pharma Europe Ltd.	21 Jun 2013
Castration-Resistant Prostatic Cancer	Liechtenstein	Astellas Pharma Europe Ltd.	21 Jun 2013
Castration-Resistant Prostatic Cancer	Norway	Astellas Pharma Europe Ltd.	21 Jun 2013
Hormone-dependent prostate cancer	European Union	Astellas Pharma Europe Ltd.	21 Jun 2013
Hormone-dependent prostate cancer	Iceland	Astellas Pharma Europe Ltd.	21 Jun 2013
Hormone-dependent prostate cancer	Liechtenstein	Astellas Pharma Europe Ltd.	21 Jun 2013
Hormone-dependent prostate cancer	Norway	Astellas Pharma Europe Ltd.	21 Jun 2013
Metastatic castration-resistant prostate cancer	United States	Astellas Pharma US, Inc.	31 Aug 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Triple-Negative Breast Carcinoma	Phase 3	United States	Astellas Pharma, Inc.	01 Sep 2016
Advanced Triple-Negative Breast Carcinoma	Phase 3	United States	MediVation, Inc.	01 Sep 2016
Advanced Triple-Negative Breast Carcinoma	Phase 3	United States	Pfizer Inc.	01 Sep 2016
Adenocarcinoma of prostate	Phase 3	United States	MediVation, Inc.	22 Jan 2014
Adenocarcinoma of prostate	Phase 3	United States	Astellas Pharma US, Inc.	22 Jan 2014
Adenocarcinoma of prostate	Phase 3	Canada	MediVation, Inc.	22 Jan 2014
Adenocarcinoma of prostate	Phase 3	Canada	Astellas Pharma US, Inc.	22 Jan 2014
Recurrent Prostate Carcinoma	Phase 3	United States	MediVation, Inc.	22 Jan 2014
Recurrent Prostate Carcinoma	Phase 3	United States	Astellas Pharma US, Inc.	22 Jan 2014
Recurrent Prostate Carcinoma	Phase 3	Canada	Astellas Pharma US, Inc.	22 Jan 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02319837 (EMBARK, ESMO2026)	Phase 3	Prostatic Cancer	1,072	Enzalutamide + Leuprolide	hgtxabeiiw(eqxtjumawx) = ifqfpmwkke lihyyopchz (ypnhnybaks, 0.1–61.0) View more	Positive	23 Oct 2026
				Leuprolide	hgtxabeiiw(eqxtjumawx) = gidxfrrfip lihyyopchz (ypnhnybaks, 2.3–60.5) View more
ESMO2026	Not Applicable	Metastatic Prostate Carcinoma	59	Enzalutamide (Whole-body TV-PSMA <129 mL)	ffwxselcpg(trdsffkjyh) = tmvjkvlxlv eyajpiswps (mhjgqyoxhd )	Negative	23 Oct 2026
				Enzalutamide (Whole-body TV-PSMA ≥129 mL)	ffwxselcpg(trdsffkjyh) = bjrudaskim eyajpiswps (mhjgqyoxhd )
NCT02446405 (ENZAMET, ESMO2026)	Phase 3	Prostate Neuroendocrine Carcinoma First line	1,125	LHRH analog + Enzalutamide	qpahrjxhcm(ibubckysgu) = znspbehcig dsmbuxxdjb (wzxjhugiqe ) View more	Positive	23 Oct 2026
				LHRH analog + NSAAs	qpahrjxhcm(ibubckysgu) = xhakvuzwoh dsmbuxxdjb (wzxjhugiqe ) View more
ESMO2026	Not Applicable	Hormone-dependent prostate cancer First line	669	Enzalutamide (ENZ)	lybjtgozgc(mgwzeyzjhi): HR = 0.91 (95.0% CI, 0.61 - 1.36) View more	Positive	23 Oct 2026
				Apalutamide (APA)
ESMO2026	Not Applicable	Hormone-dependent prostate cancer PSA	942	ADT+docetaxel	kavmlxdnxq(kutunvxyyw) = lwnbldmfbi onqrflvnpk (yjxlplfmnp ) View more	Positive	23 Oct 2026
				ADT+abiraterone/enzalutamide/apalutamide	kavmlxdnxq(kutunvxyyw) = hblnekckes onqrflvnpk (yjxlplfmnp ) View more
ESMO2026	Not Applicable	Hormone-dependent prostate cancer	1,593	Enzalutamide + Enzalutamiderivation therapy	rjtkuidyff(srhzwjfabf): HR = 0.885 (95.0% CI, 0.623 - 1.253) View more	Positive	23 Oct 2026
				Apalutamide + Apalutamideprivation therapy
ESMO2026	Not Applicable	Hormone-dependent prostate cancer	627	Apalutamide	loeuijzbct(obmrfibdrk) = 14.9% vs 2.4% bqorsuaxth (hsnichtozk ) View more	Positive	23 Oct 2026
				Enzalutamide
ESMO2026	Not Applicable	Hormone-dependent prostate cancer	1,076	ADT + apalutamide	hixlmkncjb(uurmoedrpx) = wnfhxlimkw cihhhhcewo (urtgvfptck ) View more	Positive	23 Oct 2026
ESMO2026	Not Applicable	Hormone-dependent prostate cancer androgen receptor pathway inhibitors	18,626	Apalutamide+ADT	hudbveiqlx(evtgxcygxk): HR = 1.27 (95.0% CI, 1.09 - 1.47) View more	Positive	23 Oct 2026
				Abiraterone+ADT
ESMO2026	Not Applicable	Advanced Prostate Carcinoma	26	Enzalutamide	pknvuxhbxy(gfjufulkut) = tadbvytgvf coklbypocj (xpmjfbekxa ) View more	Positive	23 Oct 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis